

## Annual Shareholders' Meeting 2021: COVID-19 pandemic underlines social relevance of Siemens Healthineers

- **Siemens Healthineers seizes crisis as opportunity and spotlights sustainable action even more**
- **Peer Schatz proposed as new Supervisory Board member**
- **Dividend proposal of EUR 0.80 per share for fiscal year 2020**

This year, the Annual Shareholders' Meeting of Siemens Healthineers AG takes place against the background of the COVID-19 pandemic: For the first time, the event will be held virtually, without the physical presence of shareholders and their proxy representatives, and with no general debate. Despite extraordinary circumstances, the Supervisory Board and the Managing Board have drawn a positive conclusion with regard to the business development: "In fiscal year 2020, Siemens Healthineers were not just content to keep the company stable in the face of historic challenges. Instead, the team saw the crisis as an opportunity to emerge stronger from it," said Supervisory Board Chairman Prof. Dr. Ralf P. Thomas.

In his speech, he pointed out that, despite the difficult conditions, the company has been able to uphold implementation of its Strategy 2025. "While the vast majority of companies were reactively engaged in coping with the crisis, Siemens Healthineers went on the offensive and opened the next chapter in the company's history with the planned acquisition of Varian Medical Systems, Inc.," said Thomas, referring to the largest transaction in the more than 100-year history of Siemens medical technology.

### **Sustainable action and business success go hand-in-hand**

Chief Executive Officer Dr. Bernd Montag also addressed the social relevance of Siemens Healthineers: "One of the most important lessons learned in recent months is that a functioning health service must be part of the critical infrastructure in every country. Health

is not primarily a cost factor but the prerequisite for quality of life in a functioning society and economy. Against this background, the value of our service to societies around the world, which we achieve for and with our customers, has become even more apparent. The pandemic has shown very clearly that we should all reconsider how we define and generate economic success and prosperity. As a company that is responsible, innovative and focused on the well-being of people, we have launched a holistic and ambitious sustainability program,” said Montag.

In the historically challenging environment of fiscal year 2020, which ended on September 30, Siemens Healthineers has proven to be highly resilient and delivered excellent results. At EUR 14.5 billion, revenue was at the record level of the previous year. And order intake for long-term large orders rose to a new high of around EUR 1 billion. This underlines the role of Siemens Healthineers as a reliable and attractive partner for its customers around the globe.

#### **Peer Schatz proposed as new Supervisory Board member**

At today’s Annual Shareholders’ Meeting, shareholders are to decide, among other things, on the election of Peer Schatz (55) as a new member of the Supervisory Board. The election of the long-time CEO of QIAGEN N.V., a leading global provider of complete solutions for gaining molecular insights from biological samples, would increase the number of Supervisory Board members of Siemens Healthineers AG from the current nine to ten. The prerequisite for this is the adoption of a resolution by the Annual Shareholders’ Meeting on an amendment to the Articles of Association that allows for a higher number of members of the Supervisory Board.

#### **Dividend proposal of EUR 0.80 per share**

In addition, the Annual Shareholders’ Meeting will decide on the dividend for the past fiscal year. The Managing Board and Supervisory Board are proposing a dividend of EUR 0.80 per share be paid for the fiscal year 2020. This corresponds to a pay-out-ratio of 60 percent of net income.

Detailed results of the voting on individual agenda items of the Annual Shareholders' Meeting will be published at <https://www.corporate.siemens-healthineers.com/investor-relations/hv>.

This press release is available at <https://www.siemens-healthineers.com/press-room/press-releases/pr-hv-2021>.

Follow the Siemens Healthineers media relations team on Twitter:

<https://twitter.com/siemenshealthpr>

### Contact for journalists

Stefan Schmidt

Phone: +49 152 02307361; e-mail: [stefansschmidt@siemens-healthineers.com](mailto:stefansschmidt@siemens-healthineers.com)

Philipp Grontzki

Phone: +49 152 03350194; e-mail: [philipp.grontzki@siemens-healthineers.com](mailto:philipp.grontzki@siemens-healthineers.com)

Ulrich Kuenzel

Phone: +49 162 2433492; e-mail: [ulrich.kuenzel@siemens-healthineers.com](mailto:ulrich.kuenzel@siemens-healthineers.com)

**Siemens Healthineers AG** (listed in Frankfurt, Germany: SHL) is shaping the future of Healthcare. As a leading medical technology company headquartered in Erlangen, Germany, Siemens Healthineers enables healthcare providers worldwide through its regional companies to increase value by empowering them on their journey towards expanding precision medicine, transforming care delivery, improving the patient experience, and digitalizing healthcare. Siemens Healthineers is continuously developing its product and service portfolio, with AI-supported applications and digital offerings that play an increasingly important role in the next generation of medical technology. These new applications will enhance the company's foundation in in-vitro diagnostics, image-guided therapy, and in-vivo diagnostics. Siemens Healthineers also provides a range of services and solutions to enhance healthcare providers' ability to provide high-quality, efficient care to patients. In fiscal 2020, which ended on September 30, 2020, Siemens Healthineers, which has approximately 54,000 employees worldwide, generated revenue of €14.5 billion and adjusted EBIT of €2.2 billion. Further information is available at [www.siemens-healthineers.com](http://www.siemens-healthineers.com).